Comparison Study of Two Treatment Modalities i.e. Calcipotriol Ointment and Calcipotriol Ointment Along With Ultraviolet Phototherapy in Special Kind of Hairloss Disorder Called as Alopecia Areata

A Randomised Comparative Study of Topical Calcipotriol (0.005%) Vs Topical Calcipotriol (0.005%) along with NBUVB Phototherapy in Patients of Alopecia Areata

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/11/006363

Enrollment

Registered

2015-11-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- PATIENTS OF ALOPECIA AREATA WITH GOOD GENERAL CONDITION AND FREE FROM ANY MAJOR SYSTEMIC ILLNESS.

Interventions

Intervention1: Topical calcipotriol (0.005%) ointment: It is a vitamin D analogue. It has therapeutic effect in various immune mediated disorders including alopecia areata to be used once a day. Inter

Eligibility

Inclusion criteria

Inclusion criteria: - Patients of any age > 5 yrs, showing features of alopecia areata - Patients with a diagnosis of patch type alopecia areata or alopecia totalis - No evidence of regrowth present at baseline. - Patient should be free from other modalities of treatment atleast for two weeks.

Exclusion criteria

Exclusion criteria: - Patients with a history of or active skin disease on the scalp such as psoriasis or seborrheic dermatitis. - Patients in whom the diagnosis of alopecia areata is in question. - Patients with active medical conditions and other comorbid conditions like infection, eczematization that in the opinion of the investigator would alter the outcome of study evaluation. - Patients with history or evidence of hematopoietic abnormality - Patients with history or evidence of renal or hepatic impairment. - Patients with history of immunosuppression or history of recurrent serious infections. - History of photodermatitis or photosensitivity - Patients taking oral corticosteroids or applying topical corticosteroids or treatment from outside. - Patients with allergy to any component of calcipotriol preparation

Design outcomes

Primary

Measure	Time frame
HAIR GROWTH ASSESSMENT WILL BE DONE CLINICALLY BY PHOTOGRAPH WITH "SEVERITY OF ALOPECIA AREATA TOOL" SCORING AND BY TRICOSCAN INITIALLY, AFTER 4 WEEKS AND FINALLY AFTER 12 WEEKS.Timepoint: 4 weeks 12 weeks or complete resolution of alopecic lesion, whichever come first	—

Secondary

Measure	Time frame
1. Continued hair density 2. Recurrence of lesion of alopecia.Timepoint: up to 10 months after completion of treatment	—

Countries

India

Contacts

Public ContactCHANDRA SHEKHAR JAISWAL

Dept. of Skin & V.D.

hitamehta88@gmail.com9429503188

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026